# Pleco Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pleco-therapeutics

- Industry: Biotechnology
- Headquarters: Netherlands
- Website: www.plecotherapeutics.com
- Total disclosed funding: $3.6M
- Latest round: Series A (Sep 5, 2022)
- Investors on record: 1

## About

Based in Nijmegen, Netherlands, and founded in 2018, Pleco Therapeutics BV, a.k.a. Pleco Therapeutics is a clinical-stage specialty biopharmaceutical company that focuses on extending the life span and enhancing the quality of life of patients through its novel Plecoid therapies that have been designed to increase the effectiveness of current cancer treatments. In September 2022, Pleco Therapeutics received EUR 5 million in a grant from Netherlands Enterprise Agency. The funding was part of a larger EUR 17.30 million a Series A, and grant round. As of September 2022, Ivo Timmermans is the CEO of the company.

The company’s product line includes PTX-061, PTX-062, and PTX-081 which are designed to detoxify the cancer-promoting cellular microenvironment. Pleco Therapeutics has also developed a model system for studying the way the sub-toxic accumulation of multiple metals interacts with cancers and chemotherapy.

Pleco Therapeutics plans to use its proceeds from September 2022 funding to complete the development of PTX-061’s regulatory dossier in AML, be ready for submission to the FDA and EMA in 2024, and accelerate preclinical work in other indications such as small-cell lung cancer.

## Funding rounds

- Series A, Sep 5, 2022, $3.6M — Oost NL

## Investors

- Oost NL (https://capitalatlas.ai/funds/oost-nl) — Series A